Clinical trials: Progressive Supranuclear Palsy (PSP)
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT07498426
- Testing
- NIO752
- Where
- 64 sites in United States, Australia and 10 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease, Osteoporosis
Trial of Parkinson's And Zoledronic Acid
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and…
- Conditions
- Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism
- Trial name
- TOPAZ (NCT03924414)
- Testing
- Zoledronic Acid 5Mg/Bag 100Ml Inj
- Where
- 77 sites in United States
- Volunteers
- 2,721 people
- Sponsor
- California Pacific Medical Center Research Institute
Progressive Supranuclear Palsy (PSP)
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT03391765
- Testing
- ABBV-8E12
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 142 people
- Sponsor
- AbbVie
PSP, PSP - Progressive Supranuclear Palsy
The CurePSP Genetics Program
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.
- Conditions
- PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS)
- Trial name
- NCT06647641
- Testing
- Whole genome sequencing will be performed at the NIH
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Progressive Supranuclear Palsy, Multiple System Atrophy
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
At present, the diagnosis of Parkinsons disease(PD) mainly relies on clinical symptoms and is easily confused with atypical Parkinsonian syndrome(APS) in the early stages. There is an urgent need for reliable biomarkers.
- Conditions
- Progressive Supranuclear Palsy, Multiple System Atrophy, Parkinson's Disease
- Trial name
- NCT06490926
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Parkinson Disease
Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy
The aim of this clinical trial is to explore the potential of novel 2nd generation tau PET radiotracers as biomarkers in cases suggestive of progressive supranuclear palsy (PSP), an atypical form of parkinsonism.
- Trial name
- Quanti-TAU-PET (NCT07105384)
- Testing
- Radiotracer
- Where
- Spain
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Progressive Supranuclear Palsy
Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
Progressive Supranuclear Palsy (PSP) is a relentlessly progressive neurodegenerative disorder, clinically characterized by parkinsonism with prominent axial involvement and postural instability, bulbar symptoms, supranuclear…
- Trial name
- NCT00385710
- Testing
- valproic acid
- Where
- 4 sites in France
- Volunteers
- 28 people
- Sponsor
- Nantes University Hospital
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT04658199
- Testing
- UCB0107 (bepranemab)
- Where
- 11 sites in Belgium, Germany and 2 more
- Volunteers
- 19 people
- Sponsor
- UCB Biopharma SRL
Progressive Supranuclear Palsy
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
The study will be conducted by the Sponsor to evaluate Twelve-months Long-Term Safety and Efficacy of GV1001 (1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy(PSP).
- Trial name
- NCT06235775
- Testing
- GV1001 1.12mg
- Where
- 5 sites in South Korea
- Volunteers
- 67 people
- Sponsor
- GemVax & Kael
Parkinson's Disease, Multiple System Atrophy
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders
This clinical trial aims to evaluate whether individualized targeted repetitive transcranial magnetic stimulation (rTMS) can improve motor and non-motor symptoms in patients with parkinsonian disorders.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- NCT07570212
- Testing
- TMS
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University First Hospital
PSP - Progressive Supranuclear Palsy, PD - Parkinson's Disease
Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy
The specific aim of this study is to investigate rod, cone and melanopsin driven pupillary light response in individuals with progressive supranuclear palsy (PSP), age-matched healthy controls and individuals with other…
- Conditions
- PSP - Progressive Supranuclear Palsy, PD - Parkinson's Disease, AD - Alzheimer's Disease, ALS (Amyotrophic Lateral Sclerosis)
- Trial name
- PMPSP (NCT03330353)
- Testing
- Pupillometry
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Massachusetts General Hospital
Vascular Parkinsonism, Drug-induced Parkinsonism
AI-Enhanced Optimization of Acute Levodopa Challenge Test
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence.
- Conditions
- Vascular Parkinsonism, Drug-induced Parkinsonism, Corticobasal Degeneration (CBD), Parkinson Disease (PD)
- Trial name
- NCT06949865
- Testing
- video recording
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Tiantan Hospital
Progressive Supranuclear Palsy
Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
This is a 12-week study of oral tolfenamic acid vs. placebo in Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04253132
- Testing
- Tolfenamic Acid
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NeuroTau, Inc.
Alzheimer's Disease, Dementia
Diagnosis and Natural History Study of Patients With Neurological Conditions
The purpose of this study is to improve understanding of neurological conditions. Patients participating in this study will continue receiving medical care, routine laboratory tests, and diagnostics tests (X-rays, CT-scans, and…
- Conditions
- Alzheimer's Disease, Dementia, Movement Disorder, Multiple System Atrophy
- Trial name
- NCT00001549
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Idiopathic Parkinson's Disease, Progressive Supranuclear Palsy
Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progressive Supranuclear Palsy.
The purpose of this research study is to evaluate safety and effectiveness of Foot Mechanical stimulation to improving Gait and Gait Related Disorders in Parkinson Disease and Progressive Supranuclear Palsy both stable and with…
- Trial name
- GONDOLAPILOTA (NCT01815281)
- Testing
- Foot Mechanical Stimulation (GONDOLA)
- Where
- 3 sites in Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele Roma
Parkinson Disease, Multiple System Atrophy
Diagnostic and Prognostic Biomarkers in Parkinson Disease
The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- PROBE (NCT00653783)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Parkinson Study Group
Progressive Supranuclear Palsy, Healthy Volunteers
Evaluation of [18F]APN-1607 as a PET Biomarker
The overall goal of this protocol is to evaluate [18F]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.
- Trial name
- NCT05005819
- Testing
- [18F] APN-1607
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro
Progressive Supranuclear Palsy
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for…
- Trial name
- NCT06355531
- Testing
- FNP-223
- Where
- 44 sites in United States, France and 7 more
- Volunteers
- 241 people
- Sponsor
- Ferrer Internacional S.A.
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS)
Safety Study of TPI-287 to Treat CBS and PSP
The purpose of this study is to determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of…
- Conditions
- Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Trial name
- TPI-287-4RT (NCT02133846)
- Testing
- TPI 287 2 mg/m2, TPI-287 20 mg/m2, TPI-287 6.3 mg/m2
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Background: Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells.
- Conditions
- Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy
- Trial name
- NCT03225144
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)